JWJunzheng Wu

Junzheng Wu

*This is an algorithmically generated author record based on publicly available information.

Junzheng Wu has a total of 78 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Blood‐derived product therapies for SARS‐CoV‐2 infection and long COVID

    by Junzheng Wu, Huichuan Yang, Ding Yu, Xiaoming Yang

    Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is capable of large‐scale transmission and has caused the coronavirus disease 2019 (COVID‐19) pandemic. Patients with COVID‐19 may experience persistent long‐term health issues, known as long COVID. Both acute SARS‐CoV‐2 infection and long COVID have resulted in persistent negative impacts on global public health. The effective application and development of blood‐derived products are important strategies to combat the serious damage caused by COVID‐19. Since the emergence of COVID‐19, various blood‐derived products that target or do not target SARS‐CoV‐2 have been investigated for therapeutic applications. SARS‐CoV‐2‐targeting blood‐derived products, including COVID‐19 convalescent plasma, COVID‐19 hyperimmune globulin, and recombinant anti‐SARS‐CoV‐2 neutralizing immunoglobulin G, are virus‐targeting and can provide immediate control of viral infection in the short term. Non‐SARS‐CoV‐2‐targeting blood‐derived products, including intravenous immunoglobulin and human serum albumin exhibit anti‐inflammatory, immunomodulatory, antioxidant, and anticoagulatory properties. Rational use of these products can be beneficial to patients with SARS‐CoV‐2 infection or long COVID. With evidence accumulated since the pandemic began, we here summarize the progress of blood‐derived product therapies for COVID‐19, discuss the effective methods and scenarios regarding these therapies, and provide guidance and suggestions for clinical treatment.


  • Novel “Z” Technique to Overcome Warping of Costal Cartilage

    by Zhe Zhang, Junzheng Wu, Zhou Yu, Yu Zhang, Juan Zhang, Baoqiang Song

    Dorsal augmentation with costal cartilage is generally used for aesthetic rhinoplasty. However, the warping tendency of costal cartilage may jeopardize the aesthetic results of rhinoplasty. Describing a new “Z” technique to overcome the warping of costal cartilage after implantation and evaluating its efficacy in vitro. A total of 31 pairs of porcine costal cartilage grafts (40 × 10 × 5 mm) were obtained and kept in Dulbecco’s Modified Eagle Medium to maintain cell viability. Paired grafts were obtained and randomly allocated for preparation by the accordion technique and the Z technique. Standardized photographs (obtained immediately after operation and at 4 weeks) were used for warping analysis. Biomechanical test was performed to measure the graft’s capacity to resist deformation by an external force. Cell viability of the grafts at 4 weeks was comparably good in the Accordion group and the Z group (61.88% ± 4.47% vs. 67.48% ± 7.03%, P = 0.55). Warping angle was comparable between the two groups (P > 0.01). The capacity to resist external force was significantly better in the Z group; the force needed to cause deformation was 3.98 ± 1.04 N in the Z group vs. 1.61 ± 0.47 N in the Accordion group in the lateral views (P < 0.0001), and 1.33 ± 0.41 N vs. 0.96 ± 0.24 N, respectively, in the frontal views (P = 0.0013). The “Z” technique appears to be a simple and effective method to minimize warping tendency of costal cartilage after implantation.

  • Open Access

    COVID-19 vaccination boosts the potency and breadth of the immune response against SARS-CoV-2 among recovered patients in Wuhan

    by Hong Liang, Xuanxuan Nian, Junzheng Wu, Dong Liu, Lu Feng, Jia Lu, Yan Peng, Zhijun Zhou, Tao Deng, Jing Liu, et al.

    The immunity of patients who recover from coronavirus disease 2019 (COVID-19) could be long lasting but persist at a lower level. Thus, recovered patients still need to be vaccinated to prevent reinfection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or its mutated variants. Here, we report that the inactivated COVID-19 vaccine can stimulate immunity in recovered patients to maintain high levels of anti-receptor-binding domain (RBD) and anti-nucleocapsid protein (NP) antibody titers within 9 months, and high neutralizing activity against the prototype, Delta, and Omicron strains was observed. Nevertheless, the antibody response decreased over time, and the Omicron variant exhibited more pronounced resistance to neutralization than the prototype and Delta strains. Moreover, the intensity of the SARS-CoV-2-specific CD4+ T cell response was also increased in recovered patients who received COVID-19 vaccines. Overall, the repeated antigen exposure provided by inactivated COVID-19 vaccination greatly boosted both the potency and breadth of the humoral and cellular immune responses against SARS-CoV-2, effectively protecting recovered individuals from reinfection by circulating SARS-CoV-2 and its variants.


  • Biological activity of a new recombinant human coagulation factor VIII and its efficacy in a small animal model

    by Junzheng Wu, Hang Zhang, Tong Lian, Yaling Ding, Chunlei Song, Dekuan Li, Liheng Wu, Tao Lei, Hong Liang


  • Open Access

    Author Correction: Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan

    by Cesheng Li, Ding Yu, Xiao Wu, Hong Liang, Zhijun Zhou, Yong Xie, Taojing Li, Junzheng Wu, Fengping Lu, Lu Feng, et al.


  • Open Access

    Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan

    by Cesheng Li, Ding Yu, Xiao Wu, Hong Liang, Zhijun Zhou, Yong Xie, Taojing Li, Junzheng Wu, Fengping Lu, Lu Feng, et al.

    To investigate the duration of humoral immune response in convalescent coronavirus disease 2019 (COVID-19) patients, we conduct a 12-month longitudinal study through collecting a total of 1,782 plasma samples from 869 convalescent plasma donors in Wuhan, China and test specific antibody responses. The results show that positive rate of IgG antibody against receptor-binding domain of spike protein (RBD-IgG) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the COVID-19 convalescent plasma donors exceeded 70% for 12 months post diagnosis. The level of RBD-IgG decreases with time, with the titer stabilizing at 35.7% of the initial level by the 9th month. Moreover, male plasma donors produce more RBD-IgG than female, and age of the patients positively correlates with the RBD-IgG titer. A strong positive correlation between RBD-IgG and neutralizing antibody titers is also identified. These results facilitate our understanding of SARS-CoV-2-induced immune memory to promote vaccine and therapy development.


  • Open Access

    Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan

    by Cesheng Li, Ding Yu, Xiao Wu, Hong Liang, Zhijun Zhou, Yong Xie, Taojing Li, Junzheng Wu, Fengping Lu, Lu Feng, et al.

    To investigate the duration of humoral immune response in convalescent coronavirus disease 2019 (COVID-19) patients, we conduct a 12-month longitudinal study through collecting a total of 1,782 plasma samples from 869 convalescent plasma donors in Wuhan, China and test specific antibody responses. The results show that positive rate of IgG antibody against receptor-binding domain of spike protein (RBD-IgG) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the COVID-19 convalescent plasma donors exceeded 70% for 12 months post diagnosis. The level of RBD-IgG decreases with time, with the titer stabilizing at 64.3% of the initial level by the 9th month. Moreover, male plasma donors produce more RBD-IgG than female, and age of the patients positively correlates with the RBD-IgG titer. A strong positive correlation between RBD-IgG and neutralizing antibody titers is also identified. These results facilitate our understanding of SARS-CoV-2-induced immune memory to promote vaccine and therapy development.